The change to open listing on the NL Prescription Drug Program reduces the administrative burden of prescribers by eliminating the special authorization process that had been in place.
Government is expanding prescription coverage for long-acting muscarinic antagonist (LAMAs) inhalers, used in the treatment of Chronic Obstructive Pulmonary Disease. The change to open listing on the NL Prescription Drug Program reduces the administrative burden of prescribers by eliminating the special authorization process that had been in place. This will ensure NLPDP beneficiaries have timely access to these inhalers for the treatment of their COPD.
Government and PAL Airlines announce connecting routes between Deer Lake, Gander and St. John's
It's National Volunteer Appreciation Week, "Volunteers Make Waves"
Bulk garbage spring clean up in Corner Brook starts tomorrow with option to drop off at Wild Cove
Winning lotto ticket sold at Pasadena Irving
Municipal Awareness is next week, celebration at the Civic Centre next Friday
